Gabriela Morales-Rivera

Partner

Boston

+1 617 570 1329

Gabriela (Gaby) Morales-Rivera is a partner in Goodwin’s nationally recognized Life Sciences group, counseling clients in the industries of biotechnology, pharmaceuticals, and medical devices. Gaby represents public and private companies in startup and formation matters, venture capital financing, initial public offerings and capital markets transactions, strategic investments, and other complex transactions.

She also represents a number of publicly traded biotechnology companies in ongoing SEC compliance and corporate governance matters. Advising companies throughout the full range of the corporate life cycle, Gaby has worked with many of her company-side clients since their initial founding and funding.

Experience

Gaby's recent client representations include the following:

Nimbus Therapeutics, LLC in connection with its $1.2 billion sale of its ACC inhibitor program to Gilead Biosciences, its financings of more than $290 million, and its $6 billion sale of its TYK2 inhibitor to Takeda Pharmaceuticals
ElevateBio, LLC in connection with its $150 million Series A financing, $193 million Series B financing, $525 million Series C financing, its $401 million Series D financing and the formation of its portfolio companies
ReNAgade Therapeutics, LLC in connection with its formation, its $300 million Series A financing and its joint venture and merger with Orna Therapeutics
MoMa Therapeutics in its formation, $86 million Series A financing and $150 million Series B financing
ROME Therapeutics with its formation, $50 million Series A financing and $149 million Series B financing
Accent Therapeutics with its $63 million Series B financing and its Series C financing
Triveni Bio with its $92 million Series A financing and $115 million Series B financing
Forma Therapeutics in connection with its $100 million Series D financing, its $319.3 million initial public offering, its $275.8 million follow-on public offering, its $200 million “at-the-market” offering, and its $1.1 billion sale to Novo Nordisk
Aptinyx in connection with its $65 million Series A financing, its $70 million Series B financing, and its $117.8 million initial public offering
Kymera Therapeutics in connection with its $30 million Series A financing, its $65 million Series B financing, its research and development collaboration with Vertex Pharmaceuticals, and its $200 million initial public offering
Exosome Diagnostics in connection with its $30 million Series C financing and its sale to Bio-Techne Corporation
Tango Therapeutics in connection with its formation, $55 million Series A financing and its $60 million Series B financing
Cullinan Oncology in its $98.5 million Series B financing, its $131.2 million Series C financing, its $287.4 million initial public offering and the formation of its portfolio companies

Bicara Therapeutics in its $108 million Series B financing, $165 million Series C financing and $362 million initial public offering
Upstream Bio with its $200 million Series B financing and $293 million initial public offering
Sionna Therapeutics with its $182 million Series C financing and $219.2 million initial public offering
Intellia Therapeutics in connection with day to day governance and reporting matters, its multiple follow-on offerings of more than $1.0 billion, its “at-the-market” offerings, its expanded licensing agreement with Regeneron Pharmaceuticals, its collaboration and spin-out transaction with Blackstone Life Sciences, and its acquisition of Rewrite Therapeutics
Akero Therapeutics in connection with its formation, $65 million Series A financing, its $70 million Series B financing, its $105.8 million initial public offering, multiple follow-on offerings of more than $425 million, a $25 million equity investment by Pfizer, Inc. its $100 million term loan facility with Hercules Capital, Inc. and day-to-day governance and reporting matters
Relay Therapeutics in connection with its formation, $57 million Series A financing, its $63 million Series B financing and its $400 million Series C financing, its $460 million initial public offering, and multiple follow-on offerings of more than $300 million, its $85 million acquisition of ZebiAI, and day-to-day governance and reporting matters
Cabaletta Bio in connection with day-to-day governance and reporting matters, its $75 million “at-the-market” offering and its follow-on offering and sale of pre-funded warrants for an aggregate of $35 million
Vigil Neuroscience in connection with day-to-day governance and reporting matters, its $91.1 million initial public offering, its $75.0 million private placement financing, its $40.0 million strategic investment from Sanofi and its “at-the-market” offering
Adicet Bio, Inc. (formerly resTORbio, Inc.) in connection with day-to-day governance and reporting matters, its $97.8 million initial public offering, the merger between Adicet Bio and resTORbio, its “at-the-market” programs, and multiple follow-on offerings of more than $300 million
X4 Pharmaceuticals in connection with day-to-day governance and reporting matters, and the sale of its priority review voucher for $105 million
Talaris Therapeutics in connection with day-to-day governance and reporting matters, its $150 million initial public offering and its “at-the-market” program
Neon Therapeutics in connection with its $106 million Series B financing, its $100 million initial public offering, and its $97 million sale to BioNTech

Areas of Practice

Capital Markets

Professional Activities

Gaby is a member of the Boston and American Bar Associations as well as the Hispanic National Bar Association.

Credentials

Education

JD

Boston University School of Law

BA

Swarthmore College

(with high honors)

Admissions

Bars

Massachusetts

Recognition & Awards

Gaby was named the Corporate Attorney of the Year at the LMG Life Sciences Americas 2025 awards and an Up and Coming Lawyer by the Massachusetts Lawyers Weekly 2025 Excellence in the Law Awards.

Gaby has been recognized by The Best Lawyers in America Ones to Watch for her work in Corporate and Technology Law and Life Sciences Practice since 2022 and has also been recognized by The Legal 500 US for her work in Capital Markets. Gaby was also shortlisted for LMG Life Sciences’ Americas 2023 US Rising Star – Financial & Corporate Award.

Gabriela Morales-Rivera

Experience

Areas of Practice

Professional Activities

Credentials

Education

JD

BA

Admissions

Bars

Recognition & Awards

Related Content

Goodwin Advises Intellia Therapeutics on $194.6 Million Pricing of Public Offering of Common Stock

Goodwin Advises Obsidian Therapeutics on Merger With Galera Therapeutics and $350 Million Private Placement Financing

Goodwin Advises Bicara Therapeutics on Closing of $172.5 Million Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Goodwin Wins Corporate Firm of the Year, Corporate Attorney of the Year, and Impact Deals of the Year at the LMG Life Sciences Americas Awards

The Legal 500 US 2025 Recognizes 44 Goodwin Practices and 172 Lawyers

Vigil Neuroscience To Be Acquired by Sanofi For $470 Million and Contingent Value Rights

Goodwin Advises Sionna Therapeutics on the Closing of its $219.2 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Goodwin Advises Akero Therapeutics on the Closing of its $402.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Technology

Life Sciences

Shareholder Activism and Takeover Defense

Life Sciences Emerging Companies

Life Sciences IPOs & Capital Markets

Venture Capital

Capital Markets

Gabriela Morales-Rivera

Experience

General Corporate Counseling and Significant Transactions

Issuer-Side Capital Markets Transactions and Representation

Areas of Practice

Professional Activities

Credentials

Education

JD

BA

Admissions

Bars

Recognition & Awards

Related Content

Goodwin Advises Intellia Therapeutics on $194.6 Million Pricing of Public Offering of Common Stock

Goodwin Advises Obsidian Therapeutics on Merger With Galera Therapeutics and $350 Million Private Placement Financing

Goodwin Advises Bicara Therapeutics on Closing of $172.5 Million Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Goodwin Wins Corporate Firm of the Year, Corporate Attorney of the Year, and Impact Deals of the Year at the LMG Life Sciences Americas Awards

The Legal 500 US 2025 Recognizes 44 Goodwin Practices and 172 Lawyers

Vigil Neuroscience To Be Acquired by Sanofi For $470 Million and Contingent Value Rights

Goodwin Advises Sionna Therapeutics on the Closing of its $219.2 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Goodwin Advises Akero Therapeutics on the Closing of its $402.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares